SLV308 (Solvay Pharmaceuticals) is a mixed partial dopamine agonist/antagonist. With low dopaminergic tone, the drug stimulates dopamine receptors; however, with high dopaminergic tone, such as after apomorphine administration, the drug antagonizes dopamine receptors. SLV308 is also a potent 5-HT1A agonist. Theoretically, this could help PD symptoms, depression and anxiety, and prevent drug-induced dyskinesia in PD. One controlled trial in PD tested doses of SLV308 ranging from 9 to 45 mg/day in 138 subjects with early PD. There was a significant improvement in motor scores, activities of daily living scores, and global impressions. Additional studies are planned (22).
Was this article helpful?